ETRM - EnteroMedics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.24
+0.30 (+15.46%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.94
Open2.03
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.98 - 2.25
52 Week Range0.04 - 30.41
Volume3,017,766
Avg. Volume776,215
Market Cap22.69M
Beta2.56
PE Ratio (TTM)-0.34
EPS (TTM)-6.5
Earnings DateMay 4, 2017 - May 8, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • EnteroMedics Announces Presentations at ObesityWeek 2017
    PR Newswire20 hours ago

    EnteroMedics Announces Presentations at ObesityWeek 2017

    ST. PAUL, Minn. , Oct. 16, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, ...

  • EnteroMedics Announces New Employee Inducement Option Grants
    PR Newswire4 days ago

    EnteroMedics Announces New Employee Inducement Option Grants

    ST. PAUL, Minn. , Oct. 12, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, ...

  • The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics

    The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics

  • 4 Momentum Stocks That May Survive the Health Policy Mess
    Zacks11 days ago

    4 Momentum Stocks That May Survive the Health Policy Mess

    In view of the current political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable momentum picks.

  • ACCESSWIRE13 days ago

    Today's Research Reports on Stocks to Watch: Mannkind and EnteroMedics

    NEW YORK, NY / ACCESSWIRE / October 4, 2017 / Mannkind and EnteroMedics saw gains yesterday after each company had positive news that had traders celebrating. Mannkind announced that the FDA has OK'ed ...

  • The Wall Street Journal13 days ago

    [$$] ReShape Owners to Receive Board Seats in EnteroMedics Deal

    The investors behind ReShape Medical Inc. will gain significant control over publicly traded EnteroMedics Inc. through a combination of the medical-device makers.

  • EnteroMedics Announces Acquisition Of ReShape Medical
    PR Newswire14 days ago

    EnteroMedics Announces Acquisition Of ReShape Medical

    "EnteroMedics and ReShape Medical are two innovative companies that share a strong strategic focus on providing proprietary, patient-friendly technologies to address the global obesity epidemic," continued Gladney.

  • EnteroMedics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
    PR Newswirelast month

    EnteroMedics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

    ST. PAUL, Minn., Sept. 12, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the company will be participating in the upcoming Ladenburg Thalmann 2017 Healthcare Conference in New York, NY. EnteroMedics' management is scheduled to present Tuesday, September 26, 2017 at 11:00AM ET. Interested parties may access a webcast of the presentation on the "Investors" section of the company's website at www.enteromedics.com. EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases.

  • Who Says Rising P/E Is Risky? 5 Top Stocks That Deny
    Zackslast month

    Who Says Rising P/E Is Risky? 5 Top Stocks That Deny

    Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.

  • Should You Buy EnteroMedics Inc (ETRM)?
    Simply Wall St.last month

    Should You Buy EnteroMedics Inc (ETRM)?

    EnteroMedics Inc (NASDAQ:ETRM), a healthcare equipment and services company based in United States, See our latest analysis for ETRM Is ETRM still cheap? Great news for investors – ETRM isRead More...

  • EnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc Therapy
    PR Newswirelast month

    EnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc Therapy

    ST. PAUL, Minn., Sept. 5, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the start of its U.S. FDA post-approval study of the vBloc® System, a medical device used to treat obesity.

  • Community Health System Divests Hospitals to Lower Debts
    Zacks2 months ago

    Community Health System Divests Hospitals to Lower Debts

    Community Health Systems, Inc. (CYH) resorts to divestitures in order to finance its long-term debts.

  • Study Concludes Vagal Nerve Blocking with EnteroMedics' vBloc Therapy is Cost-Effective
    PR Newswire2 months ago

    Study Concludes Vagal Nerve Blocking with EnteroMedics' vBloc Therapy is Cost-Effective

    ST. PAUL, Minn., Aug. 28, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that a cost-effectiveness study analyzing vBloc Therapy for the treatment of obesity was published in the American Journal of Managed Care on August 25, 2017. The study concludes that vBloc Therapy for Class II and III obese patients with diabetes and Class III obese patients without diabetes is likely to be a cost-effective alternative to conventional weight loss therapy and that vagal nerve blocking represents good value for the money from the perspective of a U.S. payer.

  • EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube2 months ago

    EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis EnteroMedics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of EnteroMedics, Inc. – LivaNova Plc, Boston Scientific Corporation, Misonix, Inc., NeuroMetrix, Inc., Natus Medical Incorporated, Johnson & Johnson, Medtronic plc and Abbott Laboratories (LIVN-US, BSX-US, MSON-US, NURO-US, BABY-US, JNJ-US, ... Read more (Read more...)

  • EnteroMedics Announces First Veterans Choice Program vBloc® Implant at MedStar Health in Maryland
    PR Newswire2 months ago

    EnteroMedics Announces First Veterans Choice Program vBloc® Implant at MedStar Health in Maryland

    ST. PAUL, Minn., Aug. 21, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that MedStar Health successfully completed its first implant of the Company's vBloc® Neurometabolic Therapy for a veteran through the Veterans Choice Program. "We are so pleased to be a part of a program that allows access to a safe, durable, non-anatomy-altering solution for patients who are battling the potentially life-threatening disease of obesity and its associated comorbidities," said Dr. Brebbia.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ETRM earnings conference call or presentation 8-Aug-17 3:30pm GMT

    Q2 2017 EnteroMedics Inc Earnings Call

  • EnteroMedics Announces Presentations Highlighting vBloc and Gastric Vest at IFSO Annual Conference
    PR Newswire2 months ago

    EnteroMedics Announces Presentations Highlighting vBloc and Gastric Vest at IFSO Annual Conference

    ST. PAUL, Minn. , Aug. 16, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: EnteroMedics and Aterna Zentaris

    NEW YORK, NY / ACCESSWIRE / August 14, 2017 / Aeterna Zentaris was a big winner on Friday despite posting a loss in its second quarter results. Trader confidence may have been a result of one analyst giving ...

  • EnteroMedics Announces Pricing of $20 Million Underwritten Public Offering
    PR Newswire2 months ago

    EnteroMedics Announces Pricing of $20 Million Underwritten Public Offering

    ST. PAUL, Minn., Aug. 11, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the pricing of an underwritten public offering of units for gross proceeds of $20 million, prior to deducting underwriting discounts and commissions and offering expenses payable by EnteroMedics. The offering consists of units, priced at a public offering price of $1,000 per unit, comprised of one share of series B convertible preferred stock, which is convertible into 435 shares of common stock at a conversion price of $2.30 per share (the "preferred stock"), and one seven-year warrant to purchase 435 shares of common stock, at an exercise price of $2.30 per share.

  • EnteroMedics Announces Proposed Underwritten Public Offering
    PR Newswire2 months ago

    EnteroMedics Announces Proposed Underwritten Public Offering

    ST. PAUL, Minn., Aug. 10, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has commenced an underwritten public offering. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), is sole book-running manager in connection with the offering. EnteroMedics intends to use the net proceeds from the offering to continue its commercialization efforts, for clinical and product development activities and for other working capital and general corporate purposes.

  • Associated Press2 months ago

    EnteroMedics reports 2Q loss

    On a per-share basis, the St. Paul, Minnesota-based company said it had a loss of 91 cents. The medical device company posted revenue of $93,100 in the period. Its adjusted revenue was $93,000. The company's ...

  • ACCESSWIRE2 months ago

    Investor Network: EnteroMedics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / EnteroMedics Inc. (NASDAQ: ETRM ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 11:30 AM Eastern ...

  • EnteroMedics Announces Second Quarter 2017 Financial Results
    PR Newswire2 months ago

    EnteroMedics Announces Second Quarter 2017 Financial Results

    ST. PAUL, Minn. , Aug. 8, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, ...

  • EnteroMedics To Discuss Business Strategy And Financial Results For The Second Quarter Of 2017
    PR Newswire2 months ago

    EnteroMedics To Discuss Business Strategy And Financial Results For The Second Quarter Of 2017

    Conference Call to be held on Tuesday, August 8, 2017 at 11:30 AM Eastern Time ST. PAUL, Minn. , Aug. 2, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical ...

  • EnteroMedics Receives Approval for Gastric Vest System Clinical Study in Spain
    PR Newswire3 months ago

    EnteroMedics Receives Approval for Gastric Vest System Clinical Study in Spain

    ST. PAUL, Minn., July 31, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the company has received approval from the Ministry of Health, Social Services, and Equality (MHSSE) in Spain through the Agency of Medicines and Medical Devices, and the CEIC Ethics Committee to initiate a clinical trial for the Gastric Vest™ System in Spain. "We are thrilled to have reached this significant clinical milestone, which supports our plans for CE Mark approval and takes us one step closer to bringing our Gastric Vest product to market," said Dan Gladney, EnteroMedics President, Chief Executive Officer, and Chairman of the Board.